-
1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
B.T. Li, David Planchard, Kōichi Goto, Egbert Frederik Smit, J. De Langen, Yasushi Goto, +13 more
39citations -
LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study
N. Colombo, E. Zsiros, Alexandra Sebastianelli, Mariusz Bidziński, Emad Matanes, K. Hasegawa, +12 more
26citations -
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆2021 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics Open access
Carsten Denkert, Michael Untch, Stephen Charles Benz, Andreas Schneeweiß, Karsten Ernst Weber, Sabine Schmatloch, +22 more
23citations -
ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
Evert S.M. van Aken, Bharti Devnani, Arsela Prelaj, Luís Castelo-Branco, Corrie A.M. Marijnen, Diogo Alexandre Martins-Branco, +21 more
22citations -
727TiP A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-32022 Annals of Oncology article Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Ghassan K. Abou-Alfa, Junbai Fan, Jeong Heo, Y. Arai, J.P. Erinjeri, Christiane Katharina Kuhl, +4 more
19citations -
Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”2022 Annals of Oncology erratum Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Peter Vogel, Andrès M.R. Cervantes, Ian Chau, Bruno Daniele, Josep Maria Llovet, Timothy Meyer, +8 more
17citations -
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer-related gene regulation Open access
M.M. Gounder, Patricia Martín-Romano, Antoîne Italiano, L. L. Siu, Philippe Alexandre Cassier, Gerald Steven Falchook, +15 more
17citations -
LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, +12 more
16citations -
Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial2021 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Josephine Lopes Cardozo, Danalyn Byng, Caroline A. Drukker, Marjanka K. Schmidt, Mary Ann E. Binuya, Laura van ‘t Veer, +5 more
16citations -
603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation2024 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Chromatin Remodeling and Cancer Open access
Robin Guo, Afshin Dowlati, Ibiayi Dagogo‐Jack, Julien Vibert, Alexander I. Spira, Victor Moreno Garcia, +12 more
15citations -
456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors2022 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer-related gene regulation Open access
S. Postel-Vinay, Antoîne Italiano, Philippe Alexandre Cassier, L.L. Siu, I. S. Lossos, J.F. Hilton, +13 more
15citations -
LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial2024 Annals of Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management Open access
M.W. Lucas, Alexander Maxwell Menzies, Marta López‐Yurda, Richard A. Scolyer, Bart A. van de Wiel, Robyn P.M. Saw, +14 more
14citations -
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis
Silvia Martin Lluesma, Urania G. Dafni, Katerina Vervita, Dimitris Karlis, Georgia Dimopoulou, Zoi Tsourti, +14 more
13citations -
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
Mariana Brandão, J.T.J.N. Hiltermann, Els Wauters, Benjamin J. Solomon, Eduardo Castañón Álvarez, Enriqueta Felip, +12 more
12citations -
60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B
Jenny Furlanetto, Federick Marme, C. Thode, Valentina Nekljudova, Y. Liu, M. Martín Jiménez, +14 more
11citations -
LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Arnaud Scherpereel, Scott Joseph Antonia, Y. Bautista, Francesco Grossi, Dariusz Mirosław Kowalski, Gérard Zalcman, +11 more
11citations -
LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma2025 Annals of Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
M.W. Lucas, Alexander Maxwell Menzies, Petros Dimitriadis, S C M A Wijnen, Marta López‐Yurda, Richard A. Scolyer, +13 more
11citations -
LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)2024 Annals of Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations Open access
G.J. Riely, M-J. Ahn, Jade Clarke, Ibiayi Dagogo‐Jack, E. Felip, Francesco Gelsomino, +14 more
10citations